Brought to you by 
Warner Chilcott gets US rights to NexMed's alprostadil for ED; rights returned
04 Apr 2017
Executive Summary
Warner Chilcott (women's health care and dermatology therapeutics) has licensed exclusive US development, marketing, and manufacturing rights to NexMed's (topical drugs) alprostadil cream, which is topically applied for erectile dysfunction (ED).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Warner Chilcott gets US rights to NexMed's alprostadil for ED; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice